Royalty Pharma plc Class A Ordinary Shares vs Charles Schwab Corporation Common Stock — how do they compare? Royalty Pharma plc Class A Ordinary Shares trades at $56.88 (market cap $25.27B), while Charles Schwab Corporation Common Stock trades at $96.93 (market cap $167.52B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 6.6× Royalty Pharma plc Class A Ordinary Shares's market cap, and Royalty Pharma plc Class A Ordinary Shares pays the higher dividend (1.66%). Which is the better fit depends on your goals — on Pluang, investors hold Royalty Pharma plc Class A Ordinary Shares for 1 Days and Charles Schwab Corporation Common Stock for 85 Days on average.
| RPRX | SCHW | |
|---|---|---|
Market Cap | $25.27B | $167.52B |
Volume | 3,671,183 | 6,554,126 |
Sector | Health | Financials |
52-Week High | $63.96 | $113.65 |
52-Week Low | $35.44 | $85.35 |
Typical Hold Time | 1 Days | 85 Days |
Enterprise Value | $32.50B | $153.97B |
Dividend Yield | 1.66% | 1.32% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Charles Schwab (SCHW) trades at $96.70, up 1.17% with bearish technical signals but strong fundamentals. The company reported record quarterly revenue of $7.08 billion (The Motley Fool, 2026-09-29) and has beaten earnings estimates for three consecutive quarters. Analyst consensus remains bullish with a $120.33 price target, representing 24% upside potential. Recent developments include dual listing on the Texas Stock Exchange and AI integration partnerships with Anthropic.
SCHW offers compelling value with a P/E of 17.64 and robust 38.79% net margin, though technical indicators signal near-term caution. The stock faces risks from narrowing interest spreads and market volatility, but strong earnings momentum and institutional support provide solid foundation for long-term growth.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →